时间:2023-12-10 15:01:24 来源:网络整理 编辑:패션
Celltrion Healthcare, South Korean biosimilar giant Celltrion’s sales unit, announced Wednesday that
Celltrion Healthcare, South Korean biosimilar giant Celltrion’s sales unit, announced Wednesday that the company has won the United Nations Development Program’s tender to supply anticancer drugs to Turkmenistan.
The UNDP is a UN agency dedicated to eradicating poverty and reducing inequalities through the sustainable development of nations in more than 170 countries and territories.
Celltrion Healthcare said the company joined the tender that opened in May this year, and that the result was announced last month.
According to Celltrion Healthcare, the company will supply its blood cancer biosimilar Truxima, and its metastatic colorectal and breast cancer treatment Vegzelma to Turkmenistan.
The company added that the supply of anticancer biosimilars is expected to begin by the end of this year.
The value of the tender, as well as the quantity of its anticancer treatments supply, have not been disclosed by the company.
“It is meaningful for us to supply our treatments to help patients in the country,” an official from Celltrion Healthcare said. “We believe that Truxima and Vegzelma will become the most effective, and economically viable treatment options, not only in developed countries but also in developing countries."
Celltrion Healthcare said that the company will participate more in international organizations’ tenders in the future.
Both Truxima and Vegzelma are widely prescribed anticancer treatments developed by Celltrion.
According to the world’s largest contract research organization IQVIA’s data, Truxima, the first biosimilar of Roche’s blockbuster cancer drug Rituxan, has secured 22 percent market share in the European market as of the second quarter this year. In the US, its market share stood at 30 percent in the third quarter, according to separate data from Symphony Health.
Vegzelma, an anti-cancer monoclonal antibody treatment biosimilar to Avastin, is increasing its presence in European countries after its launch in October 2022, Celltrion Healthcare said. The drug's market shares in Finland and Germany stood at 45 percent and 21 percent, respectively.
[News Focus] Why Kim Jong2023-12-10 14:40
Retail sales up 9.5 pct in Sept. on strong online demand2023-12-10 14:12
Over half of Koreans say they won't continue jesa: survey2023-12-10 14:09
[Exclusive] South Korean lawmakers to join international alliance taking on China2023-12-10 14:05
[KH Explains] Banks, regulators trade blame for snowballing ELS losses2023-12-10 14:04
Police slap travel ban on suspected con artist, ex2023-12-10 14:02
Nearly 1 in 3 senior pensioners look to employment to make ends meet2023-12-10 13:51
Exports of passenger cars up 16 pct in Q3 on eco2023-12-10 13:01
Yoon nominates former boss to head broadcasting watchdog2023-12-10 12:59
[Korea Beyond Korea] Historian looks back at life dedicated to Korean studies2023-12-10 12:21
[사진] 부산 깡통시장 간 윤 대통령과 기업 총수들2023-12-10 14:49
US needs 'strategic clarity' on North Korea deterrence: report2023-12-10 14:38
‘Cenozoic Life’ to open 49th Seoul Independent Film Festival2023-12-10 14:19
"식량만 달라" NLL 표류하던 北선박, 어젯밤 北이 끌고 갔다2023-12-10 13:48
Born rich, promoted young: chaebol scions become president just after 402023-12-10 13:41
[Herald Interview] Hyundai Motor takes step2023-12-10 13:33
[Exclusive] South Korean lawmakers to join international alliance taking on China2023-12-10 13:15
Nearly 1 in 3 senior pensioners look to employment to make ends meet2023-12-10 13:03
Tourism potential of Philippines, Korea discussed at GBF2023-12-10 12:55
Culture minister vows greater scrutiny over arts funding2023-12-10 12:53